TMC gave an update on TMC3 — now called TMC Helix Park — and introduced a new bioport project. Courtesy of Elkus Manfredi Architects

Within the next five to 10 years, the Texas Medical Center you know today will be double the size. That's what Bill McKeon, president and CEO of the TMC, said at yesterday's State of the Texas Medical Center event hosted by the Greater Houston Partnership.

The biggest project contributing to the TMC's growth is TMC3, a campus expansion that will bring 37 acres and 5 million square feet of space to the TMC, is now known as Helix Park. The name is a nod to the shape of the park and walkway design at the center of the campus. The TMC3 Collaborative Building — the first multi-institutional research facility in TMC’s history — will be the first of the project to deliver and is currently under construction and slated for completion in 2023.

However, the big news of the event was the TMC BioPort, the organization's upcoming biomanufacturing and medical supplies distribution engine. This new campus will span several hundred acres just down the road from TMC and will drive the much-needed repatriation of critical medical supplies and new cell and gene therapies, per a news release.

"During COVID, we saw the weakness of our supply chain," McKeon says at the event. "There is a huge effort by this country as a part of national security to make sure drug and vaccine production is moved back into the United States."

The new campus will also have an on-site upskill training center and create over 100,000 new job opportunities.

“Houston is advancing its position as the leading destination for life science discovery,” McKeon says in the release. “Through our holistic, expansive vision, we are building every vital component necessary to advance the largest life science ecosystem in the world.”

As explained at the event, the growing TMC is anchored by four districts: the TMC Medical Campus and the TMC Innovation Factory, which are already fully open and operating for years now, and the upcoming TMC Helix Park and TMC BioPort, which are both underway.


Bill McKeon gave the address at the State of the Texas Medical Center.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.